Close Menu

database

BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.

The group's CureCloud initiative combines patient health data with sequencing data from its liquid biopsy test to help oncologists select treatments.

M2Gen has seen its research database grow substantially, but now the firm must make the data useful across its clinical, pharma, and MDx partners.

The software tool, currently in development, is set to be introduced next year and could also find application in other indications such as cancer.

The findings underscore the value of carrying out large-scale human genetic analyses as part of drug target identification and validation efforts. 

 

 

The North Carolina State University team is working on scaling the technology further and may form a company to develop it commercially.

The deal expands Illumina's cloud-based data analysis portfolio and gives its customers access to tools to boost assay and operational efficiency.

The infectious disease testing firm has developed a sequencing-based coronavirus assay, which it plans to commercialize through its sister firm BioID Genomics. 

The Boston-based firm is developing a bacterial diagnostic platform to detect antibiotic resistance and help guide antibiotic treatment in hospitals. 

The Boston-based startup will use the funding to flesh out its diagnostic platform to detect antibiotic-resistant bacterial infections within a clinically relevant timeframe.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.